부산대학교 도서관

Abstract: Background & Aims: Ribavirin (RBV) is commonly used for the treatment of hepatitis C virus (HCV) infection. However, RBV is associated with a reduced quality of life (QOL). We aim to assess the impact of RBV on QOL in a real‐world setting. Methods: In a prospective study, QOL was measured by a SF‐36 questionnaire in 174 patients. In all, 85 patients were treated with RBV and 89 patients without RBV. QOL was assessed at baseline, week 12 of treatment and 24 weeks after treatment. Results: Patients treated with RBV were more likely to have HCV genotype 2 and 3 infection and cirrhosis (all P < .05). RBV‐treated patients reported lower scores for several domains of QOL already at baseline. During HCV treatment, RBV‐free treatment led to an increase in all measured dimensions of quality of life, whereas RBV treatment led to a decrease in the emotional and physical functioning. After treatment, all dimensions for QOL showed improvement across the study cohort, regardless whether RBV was part of the treatment regimen. However, 28.8%‐45.2% of treated patients perceive a sustained reduction in their physical or mental capacity after treatment, not related to RBV usage or SVR, but related to older age (P = .03) and cirrhosis (P = .02). Conclusions: During treatment, RBV leads to a reduced QOL, whereas RBV‐free treatment leads to an increased QOL. After treatment, QOL strongly increases in both, RBV and RBV‐free treated patients. Some patients perceive a sustained reduction in QOL, which seems unrelated to treatment. [ABSTRACT FROM AUTHOR]